Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).
He urged the dignitaries to collaboratively work on the identified domains of improvement and make detailed reports on them
Dr. Mandaviya and Dharmendra Pradhan dedicate Burns Centre at AIIMS; Lays foundation stone of Critical Care Hospital Building, and award 40 gold medals to meritorious students
Subscribe To Our Newsletter & Stay Updated
